Carrick Therapeutics Ltd

Based in Ireland, Carrick Therapeutics Ltd specializes in the development of innovative cancer therapies focused on treating aggressive and resistant forms of malignancies, improving patient outcomes through advanced treatment options. Carrick Therapeutics Ltd is focused on developing oncological therapies, particularly for aggressive and resistant cancers. Founded in 2015 in Dublin, Ireland, the company has engaged in 3 deals, with the most recent funding round being a Series D that raised USD 35. 00 mn from Pfizer Inc.

in November 2022. The total amount raised by the company to date is USD 35. 00 mn, with a current valuation of USD 142. 79 mn.

Tim Pearson serves as the CEO. Carrick Therapeutics specializes in developing oncological therapies targeting aggressive cancer forms. Key products include Samuraciclib, a CDK7 inhibitor, and CT7439, a CDK12/13 inhibitor, aimed at enhancing the efficacy of existing treatments for advanced breast, prostate, and ovarian cancers, including potential applications for pancreatic and Ewing's sarcoma. Collaborating with pharmaceutical companies, Carrick Therapeutics ensures its products reach oncologists and healthcare providers across the United States and Europe.

Carrick Therapeutics generates revenue through collaborations with pharmaceutical partners and clinical trials. Income is derived from co-development agreements, sharing profits based on the success of clinical trials and subsequent commercialization of products. The company's offerings, including Samuraciclib and CT7439, cater to the oncology market through B2B partnerships with hospitals and healthcare providers, integrating innovative therapies into existing treatment protocols. For the most recent year, the EBITDA was USD -15.

08 mn. In November 2022, Carrick Therapeutics Ltd raised USD 35. 00 mn in Series D funding from Pfizer Inc. This funding will support the mass production of Samuraciclib, which is intended for breast cancer treatment.

The company plans to expand its product offerings and market presence, targeting new geographic regions for its therapies. Specific timelines for product launches and regional expansions will be determined as the company progresses.